JP2016500519A5 - - Google Patents

Download PDF

Info

Publication number
JP2016500519A5
JP2016500519A5 JP2015538476A JP2015538476A JP2016500519A5 JP 2016500519 A5 JP2016500519 A5 JP 2016500519A5 JP 2015538476 A JP2015538476 A JP 2015538476A JP 2015538476 A JP2015538476 A JP 2015538476A JP 2016500519 A5 JP2016500519 A5 JP 2016500519A5
Authority
JP
Japan
Prior art keywords
vector
subject
composition
plasma
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500519A (ja
JP6454643B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2012/071297 external-priority patent/WO2014063753A1/en
Application filed filed Critical
Priority claimed from PCT/EP2013/072450 external-priority patent/WO2014064277A1/en
Publication of JP2016500519A publication Critical patent/JP2016500519A/ja
Publication of JP2016500519A5 publication Critical patent/JP2016500519A5/ja
Application granted granted Critical
Publication of JP6454643B2 publication Critical patent/JP6454643B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538476A 2012-10-26 2013-10-25 血友病の肝臓指向性遺伝子治療のためのベクター並びにその方法及び使用 Active JP6454643B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2012/071297 WO2014063753A1 (en) 2012-10-26 2012-10-26 Hyper-active factor ix vectors for liver-directed gene therapy of hemophilia 'b' and methods and use thereof
EPPCT/EP2012/071297 2012-10-26
EPPCT/EP2013/064054 2013-07-03
EP2013064054 2013-07-03
PCT/EP2013/072450 WO2014064277A1 (en) 2012-10-26 2013-10-25 Vector for liver-directed gene therapy of hemophilia and methods and use thereof

Publications (3)

Publication Number Publication Date
JP2016500519A JP2016500519A (ja) 2016-01-14
JP2016500519A5 true JP2016500519A5 (enExample) 2016-12-15
JP6454643B2 JP6454643B2 (ja) 2019-01-16

Family

ID=49554217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538476A Active JP6454643B2 (ja) 2012-10-26 2013-10-25 血友病の肝臓指向性遺伝子治療のためのベクター並びにその方法及び使用

Country Status (7)

Country Link
US (2) US11419950B2 (enExample)
EP (1) EP2911687B1 (enExample)
JP (1) JP6454643B2 (enExample)
AU (1) AU2013336601B2 (enExample)
CA (1) CA2888931C (enExample)
DK (1) DK2911687T3 (enExample)
WO (1) WO2014064277A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10398787B2 (en) 2012-10-26 2019-09-03 Vrije Universiteit Brussel Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
AU2013344375B2 (en) 2012-11-16 2017-09-14 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
ES2813367T3 (es) 2013-12-09 2021-03-23 Sangamo Therapeutics Inc Métodos y composiciones para ingeniería genómica
JP2017518082A (ja) * 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用
CN107427557B (zh) * 2014-08-13 2022-01-04 费城儿童医院 用于包装和表达变体因子viii以治疗血友病的改良表达组件
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
WO2016127057A1 (en) 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
WO2016146757A1 (en) 2015-03-17 2016-09-22 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
EP3283126B1 (en) 2015-04-16 2019-11-06 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
WO2016183422A1 (en) 2015-05-14 2016-11-17 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof
ES2886599T3 (es) 2015-06-17 2021-12-20 Poseida Therapeutics Inc Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
PE20181338A1 (es) * 2015-09-24 2018-08-21 Biomarin Pharm Inc Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
AU2016338565B2 (en) 2015-10-14 2021-11-18 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
CN115141836B (zh) * 2015-10-28 2024-08-27 桑格摩生物治疗股份有限公司 肝特异性构建体、因子viii表达盒及其使用方法
CN116479001A (zh) 2015-11-13 2023-07-25 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
TWI823830B (zh) 2015-11-13 2023-12-01 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
KR20180118659A (ko) * 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
US11191847B2 (en) 2016-04-15 2021-12-07 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia B
EP3452102B9 (en) * 2016-04-15 2024-09-04 The Trustees of The University of Pennsylvania Gene therapy for treating hemophilia a
IL262813B2 (en) * 2016-05-16 2025-12-01 Baxalta GmbH Anti-factor ix padua antibodies
WO2018049009A2 (en) 2016-09-07 2018-03-15 Sangamo Therapeutics, Inc. Modulation of liver genes
WO2018162748A1 (en) 2017-03-10 2018-09-13 Genethon Treatment of glycogen storage disease iii
EP3600445A1 (en) 2017-03-27 2020-02-05 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
EP3622065A1 (en) 2017-05-09 2020-03-18 Emory University Clotting factor variants and their use
KR102386890B1 (ko) * 2017-05-22 2022-04-15 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
KR20240170979A (ko) * 2017-07-10 2024-12-05 유니큐어 아이피 비.브이. 인간에서의 ａａｖ 유전자 요법을 위한 수단 및 방법
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
AU2019215152A1 (en) 2018-02-01 2020-08-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
JP7244547B2 (ja) 2018-02-19 2023-03-22 ホモロジー・メディシンズ・インコーポレイテッド Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
KR20210034013A (ko) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
EP3829650A4 (en) 2018-08-03 2022-05-04 Sangamo Therapeutics, Inc. IMPROVED CLINICAL PARAMETERS BY EXPRESSION OF FACTOR VIII
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
CN112912112B (zh) 2018-10-26 2024-12-17 Vrije布鲁塞尔大学 肝特异性核酸调节元件以及其方法及用途
EP3870215A1 (en) * 2018-10-26 2021-09-01 Vrije Universiteit Brussel New tools for improving gene therapy and use thereof
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US11596671B2 (en) 2019-02-01 2023-03-07 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
EP4048800A1 (en) 2019-10-23 2022-08-31 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
CN114981299A (zh) 2019-12-12 2022-08-30 武田药品工业株式会社 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
MX2023003021A (es) * 2020-09-16 2023-05-24 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
CN111926041B (zh) * 2020-10-16 2020-12-25 广州吉妮欧生物科技有限公司 一种SARS-CoV-2假病毒小鼠体内包装系统及其制备方法
WO2022187671A1 (en) * 2021-03-04 2022-09-09 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
WO2022204535A1 (en) * 2021-03-25 2022-09-29 The Johns Hopkins University Hydrodynamic gene delivery
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
AR126660A1 (es) 2021-07-28 2023-11-01 Univ Brussel Vrije Mejorando la eficacia de la terapia génica dirigida a músculos
JP2025504404A (ja) 2022-01-14 2025-02-12 アンジャリウム バイオサイエンシズ エージー Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
CN118715025A (zh) * 2022-10-08 2024-09-27 凌意(杭州)生物科技有限公司 用于增强基因表达的构建体
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體
WO2025226943A1 (en) 2024-04-25 2025-10-30 Masonic Medical Research Laboratory Polynucleotide for hepatocyte expression of vestigial like protein 4 and method of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
WO2001027303A1 (en) 1999-10-12 2001-04-19 The University Of North Carolina At Chapel Hill Adeno-associated virus vectors encoding factor viii and methods of using the same
CN101511373B (zh) * 2006-06-19 2015-12-09 阿斯克肋匹奥生物制药公司 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
WO2009071679A1 (en) * 2007-12-05 2009-06-11 Vib Vzw Novel aav vector and uses thereof
DK2282764T3 (da) * 2008-04-22 2019-10-14 Vib Vzw Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf
RU2563231C2 (ru) * 2009-06-25 2015-09-20 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Химерные молекулы фактора vii
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US10398787B2 (en) * 2012-10-26 2019-09-03 Vrije Universiteit Brussel Vectors for liver-directed gene therapy of hemophilia and methods and use thereof

Similar Documents

Publication Publication Date Title
US20230022390A1 (en) Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof
KR102057540B1 (ko) 세포, 기관 및 조직으로의 유전자 전이를 위한 ａａｖ 벡터 조성물 및 방법
KR102380265B1 (ko) 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
US11007280B2 (en) Optimized liver-specific expression systems for FVIII and FIX
US20200390866A1 (en) Factor viii sequences
RU2018136611A (ru) Генная терапия для лечения гемофилии a
US10398787B2 (en) Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
JP2018513678A5 (enExample)
Spencer et al. State of the art: gene therapy of haemophilia
RU2018143411A (ru) Лечение комплемент-опосредуемых расстройств
TW201629225A (zh) 第九因子基因療法
Vance et al. AAV Biology, Infectivity and Therapeutic Use from
WO2014063753A1 (en) Hyper-active factor ix vectors for liver-directed gene therapy of hemophilia 'b' and methods and use thereof
BR112021013874A2 (pt) Composição de ácido nucleico, vetor de terapia de gene de mamífero, partícula de vírus adeno-associado, métodos para tratar hemofilia a e para produzir uma partícula de vírus adeno-associado, e, uso de uma composição de ácido nucleico e de um vetor de terapia de gene de mamífero
WO2014016580A1 (en) Transgene expression
WO2021042944A1 (zh) 肌肉靶向的微环dna基因治疗
Khan et al. Hemophilia healing with AAV: navigating the frontier of gene therapy
ES2907741T3 (es) Polipéptidos de elabela (ELA) para uso en el tratamiento del cáncer de riñón
BR112021000695A2 (pt) métodos para tratar hemofilia a e para monitorar a eficácia da terapia gênica de fator viii de hemofilia a.
Zhou et al. Gene therapy for hemophilia A: where we stand
JP2022550954A5 (enExample)
WO2023150702A2 (en) Compositions and methods for treatment of connective tissue disorders
RU2018120484A (ru) Интратекальная доставка последовательностей нуклеиновых кислот, кодирующих abcd1, для лечения адреномиелоневропатии
Akula et al. Balancing Promise and Peril: Hemophilia Gene Therapy Insights
Brown et al. 682. Applied In Silico Engineering of Factor VIII-AAV Transgene Cassettes